vimarsana.com
Home
Live Updates
Monte Rosa Therapeutics : DDW 2024 – MRT 6160, a VAV1
Monte Rosa Therapeutics : DDW 2024 – MRT 6160, a VAV1
Monte Rosa Therapeutics : DDW 2024 – MRT 6160, a VAV1 Directed Molecular Glue Degrader, Inhibits Disease Progression in a T cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression
#Tu1727: MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin...
Related Keywords
United States ,
Boston ,
Massachusetts ,
Switzerland ,
John Castle ,
Sharon Townson ,
Markus Warmuth ,
Elisa Liardo ,
Xudong Wang ,
Shailee Vora ,
Laura Mcallister ,
Mary Zlotosch ,
Daniel Lam ,
Eswar Krishnan ,
Bowen Wallace ,
Chris King ,
Alison Paterson ,
Filip Janku ,
Bradley Demarco ,
Sophia Nguyen ,
Peter Trenh ,
Xavi Lucas ,
Debora Bonenfant ,
Ilaria Lamberto ,
Marisa Peluso ,
Foram Desai ,
Adamnr Cartwright ,
Lucas Gyger ,
,
Nanostring Autoimmune Profiling Panel ,
Monte Rosa Therapeutics Inc ,
Directed Molecular Glue Degrader ,
Inhibits Disease Progression ,
Reduced Calprotectin Expression ,
Katie May ,
Daric Wible ,
Steven De Beukelaer ,
Rosa Therapeutics Inc ,
Rosa Therapeutics ,
Future Development ,
Monte Rosa ,